Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib + Neoadjuvant Chemotherapy in TNBC
NCT00491816Phase 2Unknown
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2007
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in triple-negative breast cancer (TNBC), sponsored by University of Kansas Medical Center. Primary endpoint: Pathological Complete Response Rate at 18 weeks. Status: unknown.
02
Drugs
erlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00491816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491816.